Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES
Trader Talk Video Gallery
CNBC's Bob Pisani interviews Aretha Franklin at the NYSE.
CNBC's Bob Pisani reports on the market day live from the floor of the New York Stock Exchange.
CNBC's Bob Pisani discusses the day's market activity, live from the floor of the New York Stock Exchange.
Discussing whether an auto bailout would be good or bad for the markets, with Barry James, James Advantage Funds and CNB...
Bob Pisani reports on the trading day from the NYSE
Weighing in on the day's market action, with CNBC's Bob Pisani; Jack Gage, Forbes; Jim LaCamp, RBC Wealth Management; an...
The surge in mortgage applications proves there is pent up demand in the market, with CNBC's Diana Olick, Bob Pisani, St...
Bob Pisani reports on the trading day from the NYSE
See all Trader Talk posts
Text Size
Jun.10
4:43 PM ET
Tuesday, 10 Jun 2008
Pharmaceuticals Are Not Safe, Defensive Plays

This was a day that started out with inflation as the new global concern:

--ECB hawkish

--Fed talking tough on inflation

--Bank of Canada did not ease, when it was expected to do so

--Inflation worries roil Vietnam, that country's stock market hits a two-year low; China's Shanghai index also hits a new low

The dollar rallied as the Fed talked tough on inflation. That hurt commodity stocks like energy and materials. Financials, which have been down 5 days in a row, staged a modest but unenthusiastic rally. Big pharmaceutical stocks like Merck[MRK  Loading...      ()   ], Pfizer, Sanofi,[SNY  Loading...      ()   ] and Bristol Meyers[BMY  Loading...      ()   ] hit new lows, as the world has now discovered that these are no longer safe, defensive plays.

Everyone talking about Pfizer's [PFE  Loading...      ()   ] huge 7.1 percent dividend yield, which gets bigger every day because the stock keeps dropping. Is it safe? The $1.28 a share dividend liability costs them about $9 billion a year; even with Lipitor going off patent in 2010, Deutsche Bank estimates they will still generate $14 b in cash flow, enough to fund the dividend, even if they have to repatriate some of the sizeable amounts of cash that are parked overseas.

But let's face it folks. There are a lot of people who own Pfizer just for the dividend, and the stock is trading like they are going to cut the dividend, cash flow or not.

  related content


Questions?  Comments? 

© 2008 CNBC, Inc. All Rights Reserved

Permalink: /id/25082936

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC MOBILE  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis